Renin-angiotensin system polymorphisms and risk of hypertension: Influence of environmental factors

Journal of Clinical Hypertension

Volumn 10, Issue 6, 2008, Pages 459-466

  Forman, John P ^a   Fisher, Naomi D L ^a   Pollak, Martin R ^a   Cox, David G ^a,b   Tonna, Stephan ^a   Curhan, Gary C ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ALDOSTERONE SYNTHASE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; ARGININE; CALCIUM; CYSTEINE; DIPEPTIDYL CARBOXYPEPTIDASE; GLUTAMYL AMINOPEPTIDASE; HISTIDINE; KALLIKREIN; KALLIKREIN 1; MAGNESIUM; METHIONINE; POTASSIUM; THREONINE; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; ARTICLE; BODY MASS; CALCIUM INTAKE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DEMOGRAPHY; ENVIRONMENTAL FACTOR; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HOMOZYGOSITY; HUMAN; HYPERTENSION; NONSENSE MUTATION; POSTMENOPAUSE; POTASSIUM INTAKE; PRIORITY JOURNAL; RACE DIFFERENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; STOP CODON; VITAMIN INTAKE; CHI SQUARE DISTRIBUTION; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; QUESTIONNAIRE; RISK FACTOR;

ADULT; BODY MASS INDEX; CALCIUM, DIETARY; CHI-SQUARE DISTRIBUTION; FEMALE; GENOTYPE; HUMANS; HYPERTENSION; MIDDLE AGED; POLYMORPHISM, GENETIC; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; QUESTIONNAIRES; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; VITAMIN D;

EID: 55249112096     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.08007.x     Document Type: Article

References (48)

1. Miller JA, Scholey JW. The impact of renin-angiotensin system polymorphisms on physiological and pathophysiological processes in humans. Curr Opin Nephrol Hypertens. 2004;13:101-106.
2. Agarwal A, Williams GH, Fisher ND. Genetics of human hypertension. Trends Endocrinol Metab. 2005;16:127-133.
3. Staessen JA, Wang J, Bianchi G, et al. Essential hypertension. Lancet. 2003;361:1629-1641.
4. Reckelhoff JF, Fortepiani LA. Novel mechanisms responsible for postmenopausal hypertension. Hypertension. 2004;43:918-923.
5. Harrison-Bernard LM, Raij L. Postmenopausal hypertension. Curr Hypertens Rep. 2000;2:202-207.
6. Ahmed SB, Fisher ND, Stevanovic R, et al. Body mass index and angiotensin-dependent control of the renal circulation in healthy humans. Hypertension. 2005;46:1316-1320.
7. Kuznetsova T, Staessen JA, Brand E, et al. Sodium excretion as a modulator of genetic associations with cardiovascular phenotypes in the European Project on Genes in Hypertension. J Hypertens. 2006;24:235-242.
8. Resnick LM. The role of dietary calcium in hypertension: A hierarchical overview. Am J Hypertens. 1999;12:99-112.
9. Pfeifer M, Begerow B, Minne HW, et al. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab. 2001;86:1633-1637.
10. Li YC, Kong J, Wei M, et al. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest. 2002;110:229-238.
11. Brunner HR, Baer L, Sealey JE, et al. The influence of potassium administration and of potassium deprivation on plasma renin in normal and hypertensive subjects. J Clin Invest. 1970;49:2128-2138.
12. Tannen RL. Effects of potassium on blood pressure control. Ann Intern Med. 1983;98:773-780.
13. Whelton PK, He J, Cutler JA, et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA. 1997;277:1624-1632.
14. Jee SH, Miller ER 3rd, Guallar E, et al. The effect of magnesium supplementation on blood pressure: A meta-analysis of randomized clinical trials. Am J Hypertens. 2002;15:691-696.
15. Colditz GA. The Nurses' Health Study: A cohort of US women followed since 1976. J Am Med Womens Assoc. 1995;50:40-44.
16. Curhan GC, Knight EL, Rosner B, et al. Lifetime nonnarcotic analgesic use and decline in renal function in women. Arch Intern Med. 2004;164:1519-1524.
17. Nagatsu I, Gillespie L, Folk JE, et al. Serum aminopeptidases, "angiotensinase," and hypertension. I. Degradation of angiotensin II by human serum. Biochem Pharmacol. 1965;14:721-728.
18. Goto Y, Hattori A, Ishii Y, et al. Enzymatic properties of human aminopeptidase A. Regulation of its enzymatic activity by calcium and angiotensin IV. J Biol Chem. 2006;281:23503-23513.
19. Colditz GA, Martin P, Stampfer MJ, et al. Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol. 1986;123:894-900.
20. Korrick SA, Hunter DJ, Rotnitzky A, et al. Lead and hypertension in a sample of middle-aged women. Am J Public Health. 1999;89:330-335.
21. Fiebach NH, Hebert PR, Stampfer MJ, et al. A prospective study of high blood pressure and cardiovascular disease in women. Am J Epidemiol. 1989;130:646-654.
22. Bingham SA, Cassidy A, Cole TJ, et al. Validation of weighed records and other methods of dietary assessment using the 24 h urine nitrogen technique and other biological markers. Br J Nutr. 1995;73:531-550.
23. Brennan RE, Kohrs MB, Nordstrom JW, et al. Composition of diets of low-income pregnant women: Comparison of analyzed with calculated values. J Am Diet Assoc. 1983;83:538-545.
24. O'Donnell CJ, Lindpaintner K, Larson MG, et al. Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women in the Framingham Heart Study. Circulation. 1998;97:1766-1772.
25. Henskens LH, Spiering W, Stoffers HE, et al. Effects of ACE I/D and AT1R-A1166C polymorphisms on blood pressure in a healthy normotensive primary care population: First results of the Hippocates study. J Hypertens. 2003;21:81-86.
26. Mondry A, Loh M, Liu P, et al. Polymorphisms of the insertion/deletion ACE and M235T AGT genes and hypertension: Surprising new findings and meta-analysis of data. BMC Nephrol. 2005;6(1):1.
27. Barbalic M, Skaric-Juric T, Cambien F, et al. Gene polymorphisms of the renin-angiotensin system and early development of hypertension. Am J Hypertens. 2006;19:837-842.
28. Miyama N, Hasegawa Y, Suzuki M, et al. Investigation of major genetic polymorphisms in the renin-angiotensin-aldosterone system in subjects with young-onset hypertension selected by a targeted-screening system at university. Clin Exp Hypertens. 2007;29:61-67.
29. Tsai CT, Fallin D, Chiang FT, et al. Angiotensinogen gene haplotype and hypertension: Interaction with ACE gene I allele. Hypertension. 2003;41:9-15.
30. Staessen JA, Wang JG, Ginocchio G, et al. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular-renal risk. J Hypertens. 1997;15:1579-1592.
31. Johnson AG, Simons LA, Friedlander Y, et al. M235→T polymorphism of the angiotensinogen gene predicts hypertension in the elderly. J Hypertens. 1996;14:1061-1065.
32. Tiret L, Blanc H, Ruidavets JB, et al. Gene polymorphisms of the renin-angiotensin system in relation to hypertension and parental history of myocardial infarction and stroke: The PEGASE study. Projet d'Etude des Genes de l'Hypertension Arterielle Severe a moderee Essentielle. J Hypertens. 1998;16:37-44.
33. Vasku A, Soucek M, Tschoplova S, et al. An association of BMI with A(-6) G, M235T and T174M polymorphisms in angiotensinogen gene in essential hypertension. J Hum Hypertens. 2002;16:427-430.
34. Staessen JA, Kuznetsova T, Wang JG, et al. M235T angiotensinogen gene polymorphism and cardiovascular renal risk. J Hypertens. 1999;17:9-17.
35. Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischemic heart disease: A meta-analysis. Arterioscler Thromb Vasc Biol. 2003;23:1269-1275.
36. Stankovic A, Zivkovic M, Glisic S, et al. Angiotensin II type 1 receptor gene polymorphism and essential hypertension in Serbian population. Clin Chim Acta. 2003;327:181-185.
37. Abdollahi MR, Gaunt TR, Syddall HE, et al. Angiotensin II type I receptor gene polymorphism: Anthropometric and metabolic syndrome traits. J Med Genet. 2005;42:396-401.
38. Sugimoto K, Katsuya T, Ohkubo T, et al. Association between angiotensin II type 1 receptor gene polymorphism and essential hypertension: The Ohasama Study. Hypertens Res. 2004;27:551-556.
39. Schulman IH, Zhou MS, Raij L. Interaction between nitric oxide and angiotensin II in the endothelium: Role in atherosclerosis and hypertension. J Hypertens Suppl. 2006;24:S45-S50.
40. Schulman IH, Aranda P, Raij L, et al. Surgical menopause increases salt sensitivity of blood pressure. Hypertension. 2006;47:1168-1174.
41. Yamori Y, Liu L, Ikeda K, et al. Different associations of blood pressure with 24-hour urinary sodium excretion among pre- and post-menopausal women. WHO Cardiovascular Diseases and Alimentary Comparison (WHO-CARDIAC) Study. J Hypertens. 2001;19:535-538.
42. Fisher ND, Ferri C, Bellini C, et al. Age, gender, and non-modulation. A sexual dimorphism in essential hypertension. Hypertension. 1997;29:980-985.
43. Griffith LE, Guyatt GH, Cook RJ, et al. The influence of dietary and nondietary calcium supplementation on blood pressure: An updated metaanalysis of randomized controlled trials. Am J Hypertens. 1999;12:84-92.
44. Bucher HC, Cook RJ, Guyatt GH, et al. Effects of dietary calcium supplementation on blood pressure. A meta-analysis of randomized controlled trials. JAMA. 1996;275:1016-1022.
45. Resnick LM, Nicholson JP, Laragh JH. Calcium metabolism in essential hypertension: Relationship to altered renin system activity. Fed Proc. 1986;45:2739-2745.
46. Hamet P, Daignault-Gelinas M, Lambert J, et al. Epidemiological evidence of an interaction between calcium and sodium intake impacting on blood pressure. A Montreal study. Am J Hypertens. 1992;5:378-385.
47. Resnick L. Calcium metabolism, renin activity, and the antihypertensive effects of calcium channel blockade. Am J Med. 1986;81:6-14.
48. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004;80:1689S-1696S.